ValueAct's Ubben says firm will not seek new term on Valeant board
April 22, 2014 at 14:04 PM EDT
NEW YORK, April 22 (Reuters) - Hedge fund manager Jeffrey Ubben, whose firm ValueAct sits on the board of Valeant Pharmaceuticals, said on Tuesday that the hedge fund will not seek reelection on the board in order to devote its time on Microsoft Corp's board.
